BDH Industries Ltd (BDH)

Loading page…

BDH Industries Ltd (BDH) · mywealthgrid

About

BDH Industries Ltd operates in pharmaceuticals within India's healthcare sector, generating quarterly revenue of ₹16–17 Cr (standalone basis). At ₹316 Cr market cap and 17.46% operating margins, the company is a mid-cap player in the pharmaceutical industry.

Face value: ₹10

Market cap

₹280 Cr

P/E

30.2×

P/B

3.6×

Dividend yield

ROE

14.8%

ROCE

20.5%

Debt / equity

0.03

OPM

14.5%

EPS (TTM)

₹16.1

Book value

₹133.7

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Revenue collapsed ~40% from ₹27.11 Cr (Mar 2024) to ₹16.26 Cr (Jun 2024) and has not recovered across four subsequent quarters; verify what triggered the sharp decline and whether it reflects structural customer/product loss or cyclical headwind.
Valuation at premium to fundamentals: PE of 34.08 relative to ROE of 14.16% suggests market has priced in earnings growth not yet evident in returns; significant downside if growth expectations disappoint.
Margin inconsistency: Operating margin swings from 10.7% (Jun 2023) to 21.8% (Dec 2024) indicate operational volatility; verify whether volatility stems from cost pressures, product mix, or execution issues.
Institutional skepticism: FII 0.28% and DII 0% indicate limited institutional research and conviction; verify what factors underlie weak institutional participation.

Generated analysis · source review pending

Growth drivers

Revenue stabilization at ₹16–17 Cr (following the ₹27.11 Cr → ₹16.26 Cr drop) over four consecutive quarters provides a potential base; verify whether sector volume growth, pricing recovery, or market share gains can drive expansion from this level.
Operating margin of 17.46% demonstrates profitable operations; if revenue grows from this operational baseline without margin compression, absolute profits would expand significantly.
D/E ratio of 0.03 indicates minimal debt and substantial financial capacity for capex or acquisitions; verify capital allocation strategy and growth investment plans.

Generated analysis · source review pending

2,411 historical price candles were omitted because the exchange source has not been verified.

₹482.2-3.6%1Y

Quick read

rule-based

Pros

+High return on capital employed of 20.7%
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 254.2×
+Dividend payout of 31.3% of profit

Cons

No red flags triggered.

Research score

Structured signal from quality, growth, valuation and momentum.

43/100

Business quality: 64
Growth: 17
Valuation: 49

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	46	44	41	52	59	57	69	74	86	67	96
COGS	-30	-26	-24	-32	-36	37	49	50	60	41	70
Gross profit	—	—	—	—	—	20	20	25	26	25	26
	72	65	60	77	87	12	11	14	13	14	12
	4	5	5	7	9	9	9	11	12	12	14
OPM %	8.8%	11%	12.2%	13.1%	15.1%	14.8%	13.1%	14.7%	14.5%	17.5%	14.5%
Depreciation	1	1	—	—	1	1	1	1	1	1	1
Interest	0	0	0	1	1	0	0	0	0	0	0
	2	1	1	1	1	1	1	1	2	2	2
Profit before tax	5	5	5	7	8	9	10	11	13	12	15
Tax	2	2	1	2	2	2	2	3	3	3	4
Tax %	32.9%	33.3%	27.2%	26.2%	26.7%	27.3%	24.4%	25.8%	25.5%	25.6%	28.8%
	3	3	4	5	6	6	7	8	10	9	11
PAT margin %	7%	7.7%	9.2%	9.3%	10%	11.1%	10.4%	11%	11.5%	13.9%	11.3%
EPS (₹)	5.6	5.8	6.5	8.4	10.3	11.1	12.6	14.3	17.1	16.1	18.8
EPS adjusted (₹)	5.4	5.6	6.4	8.1	10	10.7	12.5	14.2	17.1	16.1	18.8
	35.7%	34.5%	34.4%	32.8%	24.2%	27.1%	28.7%	28.1%	26.3%	27.9%	26.6%
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	6	6	6	6	6	6	6	6	6	6	6
Reserves	21	21	25	28	32	37	43	49	56	63	71
	1	10	8	13	9	9	2	5	9	1	2
	24	14	18	18	18	19	18	20	23	17	20
Total equity & liabilities	52	52	57	66	65	71	69	80	93	87	99
	0	17	23	22	21	20	20	19	20	20	19
CWIP	—	—	—	—	—	0	0	0	—	0	0
Investments	—	—	—	—	—	0	0	0	0	0	0
	52	35	34	44	44	51	49	61	73	67	80
Total assets	52	52	57	66	65	71	69	80	93	87	99

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	35.3%	29.4%	33.3%	29.8%	37.8%	27.1%
EBITDA margin %	13.1%	15.1%	14.8%	13.1%	14.7%	14.5%	17.5%	14.5%
EBIT margin %	13.1%	13.5%	13.4%	12.2%	14%	13.8%	16.1%	13.6%
PAT margin %	9.3%	10%	11.1%	10.4%	11%	11.5%	13.9%	11.3%
Working capital
Receivable days	89	68	96	76	82	121	78	120
Inventory days	63	36	53	50	53	30	65	28
Payable days	133	113	171	123	139	128	134	91
NWC days	19	-9	-21	4	-5	23	9	57
Leverage
Current ratio	1.43	1.69	1.88	2.51	2.46	2.37	3.95	4
Debt to EBITDA	1.92	1.03	1	0.25	0.44	0.7	0.08	0.15
Debt to equity	0.38	0.24	0.2	0.05	0.09	0.14	0.01	0.03
Interest coverage	14.7	12.8	32.2	40.6	70.2	74.6	179.1	254.2
Asset turnover	0.79	0.91	0.81	1.01	0.93	0.92	0.77	0.97
Return ratios
Return on assets %	7.3%	9.1%	9%	10.5%	10.2%	10.6%	10.7%	10.9%
Return on capital employed %	22.5%	23.7%	21.7%	20%	21.4%	22.7%	18.9%	20.5%
Return on equity %	14.1%	15.5%	14.8%	14.9%	15%	15.9%	13.5%	14%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	49.66%	49.66%	49.66%	49.66%	49.66%	49.66%	49.66%	49.7%	49.7%	49.7%	49.7%	49.7%
	0%	0%	0%	0.44%	0.28%	0.28%	0.28%	0.28%	0.28%	0.28%	0.28%	0.28%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	50.34%	50.34%	50.34%	49.9%	50.06%	50.06%	50.06%	50.02%	50.02%	50.02%	50.02%	50.02%
No. of shareholders	—	—	—	—	—	—	—	—	4,889	4,800	4,746	4,587

Promoter holding up 0.04 percentage points since Sep 2023.

17 deals · 20 Sept 2022 – 11 Sept 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
11 Sept 2025	F3 ADVISORS PRIVATE LIMITED	Bulk	BSE	Buy	49,381	₹369.78	₹1.83 Cr
11 Sept 2025	F3 ADVISORS PRIVATE LIMITED	Bulk	BSE	Sell	40,119	₹362.57	₹1.45 Cr
22 Nov 2024	RAJESH MADHAVAN UNNI(HUF)	Bulk	BSE	Buy	38,825	₹333.26	₹1.29 Cr
5 Feb 2024	VRAMATH FINANCIAL SERVICES PRIVATE LIMTED	Bulk	BSE	Buy	36,723	₹241.80	₹0.89 Cr
1 Jan 2024	RAJESH MADHAVAN UNNI(HUF)	Bulk	BSE	Sell	93,242	₹262.67	₹2.45 Cr
1 Jan 2024	S.HARSHA VIJAY	Bulk	BSE	Buy	30,000	₹244.61	₹0.73 Cr
1 Jan 2024	DEBASHREE DEY	Bulk	BSE	Buy	30,000	₹262.89	₹0.79 Cr
15 Dec 2023	VRAMATH FINANCIAL SERVICES PRIVATE LIMTED	Bulk	BSE	Buy	76,000	₹189.33	₹1.44 Cr
15 Dec 2023	VRAMATH INVESTMENT CONSULTANCY PVT LTD	Bulk	BSE	Sell	76,000	₹189.33	₹1.44 Cr
21 Aug 2023	RAJESH MADHAVAN UNNI(HUF)	Bulk	BSE	Buy	29,150	₹211.57	₹0.62 Cr

1–10 of 17

1 / 2

Ms. Jayashree Gopakumar NairExecutive Director-Chairperson-MD
Mr. Suresh Chandra KachharaExecutive Director-MD
Ms. Karthika NairNon-Executive - Non Independent Director
Mr. Prabhakar Ramchandra DalalNon-Executive - Independent Director
Mr. Mitul Manubhai PatelNon-Executive - Independent Director
Mr. Suresh Chandra KookadaNon-Executive - Independent Director
Ms. Nikita PhatakCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in BDH Industries Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

46 announcementsExport CSV

25 Aug 2026, 3:32 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

17 Aug 2026, 3:02 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

14 Aug 2026, 8:52 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

14 Aug 2026, 8:25 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

14 Aug 2026, 6:53 pmResult

Standalone Unaudited Financial Results For The Quarter Ended On 30Th June 2026 Of The Financial Year 2026-27.

Financial Results PDF

14 Aug 2026, 6:45 pmBoard Meeting

Board Meeting Outcome for Outcome Of Board Meeting

Outcome of Board Meeting PDF

22 Jul 2026, 12:07 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

22 Jul 2026, 11:58 amCorp. Action

Intimation Of Record Date

Record Date PDF

Date	Category	Subject	Filing
25 Aug 2026, 3:32 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
17 Aug 2026, 3:02 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	35.3%	29.4%	33.3%	29.8%	37.8%	27.1%
EBITDA margin %	13.1%	15.1%	14.8%	13.1%	14.7%	14.5%	17.5%	14.5%
EBIT margin %	13.1%	13.5%	13.4%	12.2%	14%	13.8%	16.1%	13.6%
PAT margin %	9.3%	10%	11.1%	10.4%	11%	11.5%	13.9%	11.3%
Working capital
Receivable days	89	68	96	76	82	121	78	120
Inventory days	63	36	53	50	53	30	65	28
Payable days	133	113	171	123	139	128	134	91
NWC days	19	-9	-21	4	-5	23	9	57
Leverage
Current ratio	1.43	1.69	1.88	2.51	2.46	2.37	3.95	4
Debt to EBITDA	1.92	1.03	1	0.25	0.44	0.7	0.08	0.15
Debt to equity	0.38	0.24	0.2	0.05	0.09	0.14	0.01	0.03
Interest coverage	14.7	12.8	32.2	40.6	70.2	74.6	179.1	254.2
Asset turnover	0.79	0.91	0.81	1.01	0.93	0.92	0.77	0.97
Return ratios
Return on assets %	7.3%	9.1%	9%	10.5%	10.2%	10.6%	10.7%	10.9%
Return on capital employed %	22.5%	23.7%	21.7%	20%	21.4%	22.7%	18.9%	20.5%
Return on equity %	14.1%	15.5%	14.8%	14.9%	15%	15.9%	13.5%	14%

₹ Cr	Mar 2016	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	4	1	3	6	-2	15	-2
	-5	1	1	0	-0	2	2
	-1	-2	-8	0	1	-10	-2
Net cash flow	-1	-0	-4	7	-1	6	-2
Free cash flow	-0	1	3	6	-4	15	-2
CFO / Operating profit %	106.2%	9.2%	33.3%	57.4%	-15.1%	127.2%	-17.4%

BDH Industries Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Announcements

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Credit ratings

17

1

Compounded sales growth

Compounded profit growth

Return on equity

BDH Industries Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Credit ratings

Dividends17

Board meetings1

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

17

1